Scleral implant improving near vision with time
April 27th 2014The preliminary results of the FDA multicenter trial of the Refocus Scleral Implant (Refocus Group) for presbyopia indicated that patients had a significant increase in the near visual acuity, and that the visual acuity improved over time, according to David Schanzlin, MD.
Examining anterior chamber phakic IOL for high myopia
April 27th 2014The hydrophobic, acrylic, anterior chamber phakic IOL (AcrySof Cachet, Alcon Laboratories) performed well in a 5-year study of its safety and efficacy, according to Thomas Kohnen, MD, PhD. Most importantly, he said, the decrease in the corneal endothelial cell count was low and there were low rates of serious adverse events.
Dry eye technology more accessible
April 27th 2014TearScience announced that it will make the LipiView interferometer and LipiFlow thermal pulsation system available for individual purchase, allowing premium surgical practices to implement the innovative technology with the flexibility best suited to their individual operational strategy.
Sen. Rand Paul slams ICD-10, Obamacare
April 26th 2014Nothing was off limits as Sen. Rand Paul, MD, (R-KY) put the Affordable Care Act (ACA), the International Classification of Diseases (ICD)-10, and the U.S. government on blast for creating a gigantic headache for American patients and physicians alike.
Binkhorst Lecture: Right time for MIGS
April 26th 2014Interventional glaucoma is the new horizon for patients. Microinvasive glaucoma surgery (MIGS)-a term coined by Iqbal Ike K. Ahmed, MD-will allow for early intervention in patients with glaucoma and be safe and more effective than the medications and laser procedures used for so long with less efficacy.
Survey captures snapshot of astigmatism
April 26th 2014The 2013 ASCRS Clinical Survey Results on Astigmatism-covering 168 data points with more than 1,000 physicians responding-showed that 57% of physicians saw benefits associated with femtosecond laser arcuate incisions compared with conventional manual incisions, according to John A. Vukich, MD.
Identifying, managing dysphotopsia after cataract surgery
April 25th 2014Following cataract surgery, patients can present with a variety of visual complaints that interfere with vision after IOL implantation. Negative dysphotopsias are relative and absolute scotomas, according toJack T. Holladay, MD.
Using health policy to advocate for patients
April 25th 2014Glaucoma specialists can be advocates for their patients on a number of levels. On a daily basis, ophthalmologists help overcome barriers to treatment and offer solutions to patients for instilling medications, involving family members in their care, organizing services for patients, and providing educational materials, said Cynthia Mattox, MD, New England Eye Center, Tufts University School of Medicine, Boston.
Study finds QPI-1007 safe for patients in range of doses
April 22nd 2014One intravitreal injection of QPI-1007 (Quark Pharmaceuticals) to treat nonarteritic anterior ischemic optic neuropathy (NAION) was safe with no serious adverse events in a phase I trial, and most patients gained 3 or more lines of vision, according to Bradley Katz, MD, PhD, who reported the results on behalf of the Quark Study Group.
Study: Combined SMILE, CXL safe for keratoconus
April 15th 2014Combined small-incision lenticule extraction (SMILE) and intrastromal collagen crosslinking (CXL) to treat forme fruste keratoconus is safe, efficient, accurate, predictable, and stable for treating keratoconus for at least 1 year, according to Enrique O. Graue Hernandez, MD, MSc.
New PDUFA date for Alimera’s Iluvien
April 15th 2014Alimera Sciences’ recent resubmission of the new drug application (NDA) for its fluocinolone acetonide intravitreal implant (Iluvien) has been received by the FDA as a complete class 2 response to the agency’s October letter, and a prescription drug user fee act (PDUFA) goal date of Sept. 26 has been established.